The enzybiotics as therapeutic alternative against bacterial diseases
Keywords:
infectious diseases, microbial resistance to antibiotics, phages therapy, enzibiotics.Abstract
The constant development of the infectious diseases, together with the emergence of the microbial resistance to the antibiotics, has originated that again it is thought on the phages as therapeutic option. In fact, an important literature contribution exists about the bacteriophages and their use to eliminate infectious processes, what has justified the continuity in investigating about the possible use of them and of their genic products, as a promising alternative for treatments with antimicrobials currently available. That is why, information on these microorganisms is offered in this work, specifically on the enzibiotics, and is it intended them to be considered in the bacterial infections control.
Downloads
References
2. Mattar Y, Martínez P. Emergencia de la resistencia antibiótica debida a las β-lactamasas de espectro extendido (BLEE): detección, impacto clínico y epidemiología. Infectio. 2007 [citado 18 Feb 2015]; 11(1): 23-5. Disponible en: http://www.revistainfectio.org/index.php/infectio/article/view/136/170
3. González Lorenzo A. Resistencia antimicrobiana “in vitro”. Sistema Diramic 10. Un año de experiencia. Rev Méd Electrón. 2003 [citado 12 Feb 2015]; 25(6). Disponible en: http://www.revmedicaelectronica.sld.cu/index.php/rme/article/view/123/html
4. Harbarth S, Theuretzbacher U, Hackett J, DRIVE-AB consortium. Antibiotic research and development: business as usual? J Antimicrob Chemother. 2015; 70(6): 1604-7.
5. D’Hérelle F. Sur une microbe invisible antagoniste des bacilles dysentérique. C R Acad Sci (Paris). 1917; 165: 373-5.
6. Twort FW. An investigation on the nature of ultramicroscopic viruses. Lancet. 1915; 186(4814): 1241-3.
7. Nallelyt Segundo A, Efrén Hernández B, Oliver López V, Oscar Torres A. Los bacteriófagos como una alternativa en el tratamiento de enfermedades infecciosas bacterianas (fagoterapia). Rev Mex Ciencias Farmac. 2010 [citado 18 Feb 2015]; 41(3). Disponible en: http://www.redalyc.org/pdf/579/57916078003.pdf
8. Tamariz JH, Lezameta L, Guerra H. Fagoterapia frente a infecciones por Staphylococcus aureus meticilino resistente en ratones. Rev Peru Med Exp Salud Publica. 2014 [citado 18 Feb 2015]; 31(1): 69-77. Disponible en: http://www.scielosp.org/scielo.php?script=sci_arttext&pid=S1726-46342014000100010&lng=en&nrm=iso&tlng=en
9. Nilsson AS. Phage therapy--constraints and possibilities. Ups J Med Sci. 2014; 119(2): 192-8.
10. Dulbecco R. Multiplicación y genética de bacteriófagos. En: Davis B, Dulbecco D, Eisen N, Ginsberg S. Tratado de Microbiología. 4 ed. Barcelona: Masson; 1996. p. 760-80.
11. García E, López R. Los bacteriófagos y sus productos génicos como agentes antimicrobianos. Rev Esp Quimioterapia. 2002; 15(4): 306-12.
12. Sulakvelidze A, Alavidze Z, Morris G. Bacteriophage therapy. Antimicrob Agents Chemother. 2001; 43(3): 649-59.
13. Lozano S. Félix D´Herelle. Aportes a biografía de un pasteurizado en México (1904-1911). Rev Electrónica Latinoamericana de Estudios Sociales, Históricos y Culturales de la Ciencia y la Tecnología. 2006 [citado 20 Mar 2015]; 1(1) 1-15. Disponible en: http://www.saber.ula.ve/bitstream/123456789/18359/1/articulo2.pdf
14. Hermoso JA, García JL, García P. Taking aim on bacterial pathogens: form phage therapy to enzybiotics. Curr Opin Microbiol. 2007; 10(5): 461-7.
15. López García R. Bacteriófagos: de la biología molecular a su uso terapéutico. Anales de la Real Academia de Ciencias Veterinarias. 2005; 13(13):61-74.
16. Ronda C, Vázquez M, López R. Los bacteriófagos como herramienta para combatir infecciones en acuacultura. Revista AquaTIC. 2003 [citado 20 Mar 2015]; 18:3-10. Disponible en: http://www.revistaaquatic.com/aquatic/pdf/18_2.pdf
17. Gill JJ, Pacan JC, Carson ME, Leslie KE, Griffiths MW, Sabour PM. Efficacy and pharmacokinetics of bacteriophage therapy in treatment of subclinical Staphylococcus aureus mastitis in lactating diary cattle. Antimicrob Agents and Chemiother. 2006; 9(50): 2912-8.
18. Chow MS, Rouf MA. Isolation and partial characterization of two Aeromonas hidrophila bacteriophages. Appl Environ Microbiol. 1983; 5(45): 1670-6.
19. Wattanabe R, Matsumoto T, Sano G, Ishii Y, Tateda K, Sumiyama Y, et al. Efficacy of Bacteriophages therapy against gut-derived sepsis caused by Pseusomonas aeruginosa in mice. Antimicrob Agents Chemiother. 2006; 51(2): 446-52.
20. Qadir MI. Review: phage therapy: a modern tool to control bacterial infections. Pak J Pharm Sci. 2015; 28(1):265-70.
21. Rose T, Verbeken G, Vos DD, Merabishvili M, Vaneechoutte M, Lavigne R, et al. Experimental phage therapy of burn wound infection: difficult first steps. Int J Burns Trauma. 2014; 4(2): 66-73.
22. Chan BK, Abedon ST. Bacteriophages and their enzymes in biofilm control. Curr Pharm Des. 2015;21(1):85-99.
Published
How to Cite
Issue
Section
License
All the articles can be downloaded or read for free. The journal does not charge any amount of money to the authors for the reception, edition or the publication of the articles, making the whole process completely free. Medisan has no embargo period and it is published under the license of Creative Commons, International Non Commercial Recognition 4.0, which authorizes the copy, reproduction and the total or partial distribution of the articles in any format or platform, with the conditions of citing the source of information and not to be used for profitable purposes.
![Secimed](/templates/images/secimed.png"){kind=small}
